THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era Monday, March 9, 2026

COMPOUND WATCH

Orforglipron (Lilly, oral non-peptide GLP-1) [Phase 3] ACHIEVE-3 trial published in The Lancet today. 52 weeks, n=1,698 adults with T2D on metformin. Head-to-head vs. oral semaglutide 14mg:

The discontinuation range reflects multiple dose arms — the 8.7% figure corresponds to lower doses, 9.7% to higher. Dose-dependent tolerability is real and will matter in post-approval real-world data. The no-food-restriction advantage is clinically meaningful: oral sema's 30-minute fasting window is a genuine adherence barrier that orforglipron eliminates entirely.

One critical fact for this readership: orforglipron is a novel non-peptide small molecule — it cannot be compounded under current FDA rules. There is no compounded version pathway. If approved Q2 2026, your only access route is branded Lilly product. This closes one oral GLP-1 compounding pathway at the same moment the RFK reclassification may open others.

CagriSema (Novo Nordisk) [Phase 3] REDEFINE 1 confirmation: 22.7% mean weight reduction at 68 weeks vs. 16.1% semaglutide monotherapy vs. 2.3% placebo. 46.8% of CagriSema patients hit ≥25% weight loss. NDA submitted. Current ceiling for the injectable class.

Olatorepatide (Regeneron/Hansoh, dual GLP-1/GIP) [Phase 3] Positive Phase 3 data today: once-weekly injectable, 48 weeks, n=604 across 33 China sites. Up to 19% mean body weight loss. Nausea <10%, vomiting <5% — claimed lower GI adverse event rates than other published dual incretin Phase 3s. Caveat: China-only trial. Regeneron's global Phase 3 initiating soon. If tolerability holds globally, this is a tirzepatide-level competitor with a better GI profile claim.

BPC-157 [Animal — zero published human RCTs] New risk flag, and it's not nothing. A University of Utah paper in Current Reviews in Musculoskeletal Medicine — cited today in GQ's mainstream peptide feature — notes BPC-157 could theoretically promote tumor cell growth. To be precise: GQ is characterizing the paper, not the paper itself. If you want to pull the primary source, search the journal directly rather than relying on GQ's characterization. This is in vitro/theoretical — not a clinical signal. But it's the first credible academic flag on the compound's risk profile in mainstream literature. The zero-human-RCT baseline means we genuinely don't know the long-term oncology risk. Anyone injecting BPC-157 is doing so on animal data and community reports alone. Watch, don't panic — but track it.

GLP-1 Weight Regain [Phase 3 — meta-analysis] New eClinical Medicine meta-analysis: 48 studies, primary model from 6 RCTs (n=3,236). Patients regained 60% of lost weight within one year of stopping GLP-1 drugs. Rapid rebound immediately post-cessation, decelerating toward plateau. Agents studied: liraglutide, semaglutide, tirzepatide, others. This is the number that ends the "I'll use it for a year and stop" plan for most people — and the number that makes indefinite access to affordable supply a clinical necessity, not a lifestyle choice.

VENDOR SIGNAL

No Finnrick rating changes, failed HPLC tests, or new Janoshik results surfaced today. Check finnrick.com directly before your next order.

What did surface is structurally more important than any single test result.

Research peptide vendors — RUO shield cracking [Flagged — regulatory risk escalating] A Lexology/Sheppard analysis published today states explicitly that FDA now considers "research use only" labeling "no longer a viable shield when the intended use — human consumption — is obvious from the surrounding marketing." This is the first time regulatory attorneys have put this in writing as an active FDA posture, not a theoretical risk. Every gray-market peptide vendor running a storefront with dosing guides, before/after photos, and "for research purposes only" fine print is operating on borrowed time. No criminal enforcement against research peptide vendors confirmed today — but the legal architecture protecting QSC, Amino Asylum, and others is now explicitly in the FDA's crosshairs.

Practical action: If you're sourcing from [COA Only] or [Unverified] vendors, this is the week to get independent verification. Per community testing aggregates (treat as directional, not precise), roughly 15–20% of supplier COAs show discrepancies when independently tested. You're injecting this. Finnrick HPLC data is your best available tool.

TGA counterfeit GLP-1 alert (Australia) [Flagged] Lab testing confirmed multiple imported products marketed as GLP-1 therapies contain zero GLP-1 or GLP-1 analogue. Named products: HHVB GLP-1 Moringa Slimming & Health Boost Drops, Croaie Tipoleptide GLP-1 + GIP Weight Management, BuildLeaf Tirzepatide GLP-1 Herbal Oral Liquid, STDEI GLP-1 Weight Loss Oral Solution. Consumer-facing counterfeits, not U.S. research vendors — but the pattern is global. If you're sourcing anything GLP-1-adjacent from outside established U.S. channels, independent testing is not optional.

TRIAL TRACKER

BPC-157 — First Human RCT [Phase 2 | Recruiting] NCT07437547: "BPC 157 for Acute Hamstring Muscle Strain Repair." Started February 2, 2026. This is the trial the entire community has been waiting for. BPC-157 has been injected by hundreds of thousands of people on animal data alone. Phase 2 means we're in safety/dosing territory, not efficacy proof — but it exists. Every prior claim about BPC-157 for tendon/muscle repair has been [Animal] or [Anecdotal]. This trial begins generating actual human data.

Retatrutide (Lilly triple agonist, GLP-1/GIP/glucagon) [Phase 3 | Recruiting] NCT07357415: Recruiting as of January 24, 2026 — adults without T2D, obesity/overweight. Phase 2 showed ~24% weight loss, highest of any injectable in the class. Phase 3 will determine whether that holds. If it does, retatrutide becomes the ceiling-setter above CagriSema's 22.7%. Sourcing implication: once Phase 3 data drops, expect compounding demand to shift toward retatrutide analogs on the gray market — same pattern as tirzepatide's rise.

Amylin analogues — horizon watch [Phase 2 | Early] Metabolic Weekly flags amylin analogues as the emerging post-GLP-1 class. No sourcing implications today. File for the 12-month horizon — the same gray-market demand cycle that followed GLP-1 approvals will likely follow amylin analogues if Phase 3 data materializes.

THE ODDS

Polymarket probabilities — translated for peptide practitioners

Inflation >3% in 2026: 80% probability ($115K volume) Current 503A tirzepatide runs $200–500/month depending on dose and compounder. A 5–10% price creep — directional estimate based on API, excipient, and sterile compounding labor exposure to sustained inflation — means $10–50/month more by Q3 2026 if you're at the top of that range. Gray-market pricing is more volatile; Chinese vendor prices in USD are also inflation-exposed via currency dynamics. The $2–5 Chinese factory price for peptide API has historically been sticky, but U.S. compounding overhead is not.

U.S. Recession by end of 2026: 32% probability ($516K volume) Below the threshold where you'd expect mass defection from compounding pharmacies to gray-market vendors. In a recession scenario, the math flips: $49/month gray-market tirzepatide vs. $350/month compounder becomes a harder choice. As a rule of thumb — not a sourced threshold — if this crosses ~45%, expect a visible shift in r/peptides toward QSC/SRY sourcing discussions and away from 503A/503B recommendations. Watch the number, not the current level.

No Fed rate cuts in 2026: 23% probability ($1.84M volume — real money) The inverse: 77% odds of at least one cut. Mild tailwind for discretionary health spending. People financing $300–500/month peptide stacks on credit cards care about rate direction. Not a dominant signal today, but it's the macro backdrop that keeps the $300/month biohacker solvent.

The macro picture: inflation likely stays elevated, recession risk real but not dominant, rates probably ease. Net for your sourcing: compounder prices drift up $10–50/month, gray-market looks relatively cheaper, but the regulatory net around gray-market is tightening simultaneously. The squeeze is real.

SIGNAL VS. NOISE

SIGNAL: Hims & Hers capitulates to Novo Nordisk The deal announced today is structural. Hims will sell branded Ozempic, injectable Wegovy, and oral Wegovy pill at standard telehealth prices. Hims will no longer promote compounded GLP-1s in advertising. Existing patients get offered the switch. This follows Hims' compounded oral semaglutide pill being launched and pulled within days in February 2026, an HHS referral to DOJ, and a Novo lawsuit. The largest compounded GLP-1 telehealth platform just exited the compounded market. To be precise: this is the writer's interpretation of the causal chain — the HHS/DOJ referral and Novo lawsuit created legal exposure that made the economics untenable. The actual sequence is messier than a clean narrative. But the outcome is unambiguous: if you were using Hims for cheap compounded sema, that option is gone.

The immediate decision this creates: If you're a current Hims compounded oral sema patient being offered the switch to branded oral Wegovy, the key question is price differential. Branded oral Wegovy pricing through telehealth platforms isn't confirmed in today's data — ask your provider for the specific number before accepting the switch. What is confirmed: the oral Wegovy pill has launched and is [per BioPharma Dive] "off to a very fast start" in early prescription totals. It's a real product. Whether it's affordable at your income level is the question you need answered before your next refill decision.

SIGNAL: Orforglipron beats oral semaglutide head-to-head in Phase 3 — and can't be compounded A 26-percentage-point gap in A1c target attainment (76.8% vs. 50.9%) in a 1,698-person RCT is not noise. Neither is the no-food-restriction advantage. But the compounding-ineligibility is the signal that matters most for this readership: if orforglipron gets approved Q2 2026, there is no compounded version. Your access is branded Lilly product only.

SIGNAL: GLP-1 weight regain meta-analysis — 60% within one year Six RCTs, 3,236 patients. This isn't a rat study or a Telegram anecdote. It's the number that makes indefinite access to affordable GLP-1 supply a medical necessity for most users — and makes the Hims capitulation more consequential for people who can't afford $900+/month brand Ozempic.

SIGNAL: BPC-157 tumor promotion flag Theoretical, in vitro, not clinical. But from a credible academic source (University of Utah, peer-reviewed journal). First time this risk has been flagged in mainstream literature. Not a reason to stop — a reason to track, and a reason why the first human Phase 2 RCT (NCT07437547) matters.

NOISE: "Hot Peptide Summer" mainstream media framing GQ's piece is good journalism. The consumer amplification of RFK's Joe Rogan comments is noise until there's a Federal Register notice. No formal FDA reclassification has occurred. No rule has been issued. The GQ piece will drive r/peptides traffic and a short-term demand spike — it doesn't change your sourcing options today.

NOISE: Harper's Bazaar peptide stacking trend coverage CJC-1295/Ipamorelin combos and the "Wolverine Stack" (BPC-157 + TB-500) are not new. The TikTok/Bazaar coverage is a lagging indicator of community trends, not a leading one. Evidence grades unchanged: CJC-1295/Ipamorelin [Animal/Anecdotal], BPC-157 [Animal — first human Phase 2 just started], TB-500 [Animal]. Mainstream coverage doesn't upgrade the evidence.

REGULATORY RADAR

FDA — 30 warning letters (March 3, made public this week) Named recipients include Kin Meds, GoodGirlRx, WeightCare, and PharmaZee. Primary violations: (1) implying sameness with FDA-approved GLP-1 products; (2) branding compounded products under telehealth firms' own trademarks to obscure sourcing. Companies have 15 business days from March 3 to respond — deadline approximately March 24. Non-compliance escalates to consent decrees or injunctions, which are the actions that actually remove supply from the market. The Frier Levitt analysis frames this alongside the Hims deal as the formal end of mass-market compounded GLP-1s. FDA Commissioner Makary: "It's a new era."

RUO Shield — explicitly targeted As noted in VENDOR SIGNAL: "research use only" labeling is now explicitly in FDA's enforcement logic when human consumption intent is obvious from marketing context. No raids on research peptide vendors confirmed today — but the legal theory that has protected them is now officially contested.

RFK Jr. peptide reclassification — still a podcast, not a rule No Federal Register notice. No formal FDA action. GQ's mainstream coverage amplifies the signal; the regulatory status is unchanged. RFK said ~14 of 19 Category 2 peptides would move back to Category 1 "in the coming weeks" — that was approximately two weeks ago. The specific trigger to watch for: a notice in the Federal Register under 21 CFR Part 216, or a formal FDA guidance document. A tweet, a press release, or another podcast appearance does not change your sourcing options. If you see a Federal Register notice, that's the green light to contact your compounder — not before. Manufacturing ramp-up will take at least 4–8 weeks after any formal announcement (directional estimate). Don't pre-order based on a podcast.

India semaglutide patent expiry — March 21, 2026 Multiple Indian generics approved or pending: Sun Pharma, Zydus, Alkem, Dr. Reddy's ("Obeda" brand), Torrent, MSN. Generic semaglutide expected at ₹3,000–5,000/month (~$35–60 USD). Gray-market risk flag: within days of March 21, expect India-sourced generic sema threads on r/peptides. These products will be completely unverified — no Finnrick ratings, no established COA track record, no U.S. testing infrastructure. Treat any India-sourced generic sema as [Unverified] until independent HPLC data exists, regardless of price. For context on how fast this market moves: semaglutide's India volume share jumped from 13% to 21% in just two months following Novo's November 2025 price cuts — the demand appetite for cheaper sema is real and will pull gray-market supply quickly.

503B policy — active debate A RealClearHealth op-ed today argues 503B outsourcing facilities should receive expanded production authority to match 503A pharmacies — framing it as a supply chain resilience issue. Only 72 registered 503B facilities remain in the U.S. Each Hims-style capitulation concentrates more of the legitimate compounding market into fewer facilities. If you're relying on 503B supply chains, compounder diversification is not paranoia — it's risk management.

NUMBERS THAT MATTER

60% — Weight regained within one year of stopping GLP-1 drugs (6 RCTs, n=3,236). Makes "temporary use" a medically incoherent plan for most patients.

22.7% / 16.1% / 2.3% — CagriSema / semaglutide monotherapy / placebo weight reduction at 68 weeks. 46.8% of CagriSema patients hit ≥25% weight loss. Current injectable class ceiling.

76.8% vs. 50.9% — Proportion reaching A1c ≤6.5% on orforglipron 36mg vs. oral sema 14mg. A 26-point gap in a head-to-head RCT. Orforglipron cannot be compounded.

19% — Olatorepatide mean body weight loss at 48 weeks (Phase 3, China, n=604). Nausea <10%, vomiting <5%. If tolerability holds globally, tirzepatide-level efficacy with a better GI profile claim.

8.7–9.7% vs. 4.5–4.9% — Orforglipron vs. oral sema discontinuation rates in ACHIEVE-3. The range reflects multiple dose arms; higher doses correlate with higher discontinuation. Efficacy advantage comes with a real tolerability cost — watch post-approval real-world data.

13% → 21% — Semaglutide's India volume market share gain in two months. Tirzepatide still holds 79% volume / 85% value share. Generic sema launches March 21.

~$35–60/month — Expected generic semaglutide price in India post-March 21. Compare: $900+/month brand Ozempic, $200–500/month U.S. compounder, $49/month Hims compounded (now discontinued).

$10–50/month — Estimated 503A compounder price creep by Q3 2026 if inflation stays above 3% (directional estimate; based on 5–10% increase on current $200–500/month range).

72 — Registered 503B outsourcing facilities remaining in the U.S. Supply chain concentration risk is rising with every Hims-style exit from the compounded market.

15 business days from March 3 — FDA warning letter response deadline for Kin Meds, GoodGirlRx, WeightCare, PharmaZee. ~March 24. Non-compliance = escalation to injunctions.

WHAT TO WATCH

March 21: India semaglutide patent expiry. Sun Pharma, Zydus, Dr. Reddy's ("Obeda"), Torrent, MSN generics launch. Watch r/peptides for India-sourced generic sema threads within days. Treat all as [Unverified] until independent HPLC testing appears. The $35–60/month price point will be compelling — the verification infrastructure won't exist yet.

~March 24: FDA warning letter response deadline for Kin Meds, GoodGirlRx, WeightCare, PharmaZee. Watch for consent decrees or injunctions — those are the actions that remove supply from the market, not the warning letters themselves.

Next 2–4 weeks: RFK formal FDA reclassification announcement (or not). Watch for a Federal Register notice under 21 CFR Part 216 — not a tweet, not a press release, not a podcast. A published rule means manufacturing ramp-up begins; expect 4–8 weeks before supply normalizes (directional estimate). If you're waiting to restock BPC-157 or TB-500 from a compounder, the Federal Register is your trigger, not GQ.

Q2 2026: Orforglipron FDA obesity decision. If approved: no compounded version exists or can exist. Watch for compounding demand to shift toward other oral GLP-1 formulations — or toward retatrutide analogs on the gray market as Phase 3 data matures.

Ongoing: Check finnrick.com before your next order. No vendor rating changes today, but the RUO enforcement signal means the vendor landscape is under more pressure than it was last week.

The structural story of this week: the cheap compounded GLP-1 era is contracting. Hims is out. 30 telehealth firms are under warning. The RUO shield is cracking. The 60% regain data means most users need indefinite access. The math between those two facts is the problem your sourcing strategy has to solve.

Reply to this email with feedback — what are you reconstituting right now, and what do you need me to track?

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $5/month.